tegeprotafib   Click here for help

GtoPdb Ligand ID: 12884

Synonyms: compound 124 [US20230019236A1]
Compound class: Synthetic organic
Comment: The structure for tegeprotafib was obtained from proposed INN list 129 (August 2023) where it is described as a protein tyrosine phosphatase (PTP) inhibitor and antineoplastic agent. It is claimed in patent WO2021127499A1 as an inhibitor of PTPN1 and/or PTPN2 [1], for the treatment of disorders and conditions that will respond to PTPN1/PTPN2 inhibition (e.g. cancer).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 104.32
Molecular weight 326.3
XLogP 0.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC1=CC2=C(C(=C(C=C2C=C1)O)N3CC(=O)NS3(=O)=O)F
Isomeric SMILES FC1=C(C(=CC2=CC=C(C=C12)OC)O)N3CC(NS3(=O)=O)=O
InChI InChI=1S/C13H11FN2O5S/c1-21-8-3-2-7-4-10(17)13(12(14)9(7)5-8)16-6-11(18)15-22(16,19)20/h2-5,17H,6H2,1H3,(H,15,18)
InChI Key CPLSFGHDGOFDRP-UHFFFAOYSA-N
References
1. Farney EP, Shiroodi RK, Xiong Z, Zhang Q, O'connor M, Halvorsen GT, Zhao H, Baumgartner C, Frost JM, Kym PR et al.. (2021)
Protein tyrosine phosphatase inhibitors and methods of use thereof.
Patent number: WO2021127499A1. Assignee: Calico Life Sciences Llc, Abbvie Inc.. Priority date: 18/12/2020. Publication date: 24/06/2021.